Australia markets closed

Crinetics Pharmaceuticals, Inc. (CRNX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
49.50-1.12 (-2.21%)
At close: 04:00PM EDT
49.50 0.00 (0.00%)
After hours: 04:02PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 3.90B
Enterprise value 3.06B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.57k
Price/book (mrq)4.46
Enterprise value/revenue 1.55k
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.63
52-week change 3122.87%
S&P500 52-week change 329.31%
52-week high 352.03
52-week low 315.76
50-day moving average 345.47
200-day moving average 334.38

Share statistics

Avg vol (3-month) 3866.07k
Avg vol (10-day) 3997.24k
Shares outstanding 578.86M
Implied shares outstanding 680.64M
Float 873.44M
% held by insiders 12.11%
% held by institutions 1105.74%
Shares short (30 Apr 2024) 44.91M
Short ratio (30 Apr 2024) 46.35
Short % of float (30 Apr 2024) 46.36%
Short % of shares outstanding (30 Apr 2024) 46.23%
Shares short (prior month 28 Mar 2024) 44.91M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-11,488.91%

Management effectiveness

Return on assets (ttm)-24.01%
Return on equity (ttm)-40.76%

Income statement

Revenue (ttm)1.97M
Revenue per share (ttm)0.03
Quarterly revenue growth (yoy)-76.10%
Gross profit (ttm)N/A
EBITDA -246.87M
Net income avi to common (ttm)-235.46M
Diluted EPS (ttm)-3.77
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)900.96M
Total cash per share (mrq)11.43
Total debt (mrq)52.5M
Total debt/equity (mrq)6.00%
Current ratio (mrq)17.72
Book value per share (mrq)11.14

Cash flow statement

Operating cash flow (ttm)-178.44M
Levered free cash flow (ttm)-99.77M